Subscribe
istock-509483224-pills-1
txking / iStockphoto.com
14 February 2018Americas

Sumitomo sues over antipsychotic drug

Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.
Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Big Pharma
EU General Court issues mixed ruling in pharma TM clash
14 June 2018   The EU General Court today ruled on a pharmaceutical trademark dispute over the names ‘Emcur’ and ‘Emcure’, finding similarity for some goods and services but not others.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.
Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Big Pharma
EU General Court issues mixed ruling in pharma TM clash
14 June 2018   The EU General Court today ruled on a pharmaceutical trademark dispute over the names ‘Emcur’ and ‘Emcure’, finding similarity for some goods and services but not others.

More on this story

Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.
Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Big Pharma
EU General Court issues mixed ruling in pharma TM clash
14 June 2018   The EU General Court today ruled on a pharmaceutical trademark dispute over the names ‘Emcur’ and ‘Emcure’, finding similarity for some goods and services but not others.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility